Variable | Univariate Analysis | Multivariate Model # 1 Maximum Core Only | Multivariate Model #2 MIBC + Percent Positive Cores | Multivariate Model #3 MIBC + Percent Cancer Volume | ||||
---|---|---|---|---|---|---|---|---|
p-value | Hazard Ratio (95% CI) | p-value | Hazard Ratio (95%CI) | p-value | Hazard Ratio (95%CI) | p-value | Hazard Ratio (95%CI) | |
Age | 0.62 | 0.99 (0.97-1.02) | 0.23 | 0.99 (0.96-1.01) | 0.40 | 0.99 (0.97-1.01) | 0.48 | 0.99 (0.97-1.02) |
PSA | <0.0001 | 5.7 (3.6-9.5) | <0.0001 | 4.6 (2.3-9.3) | <0.0001 | 4.7 (2.3-9.7) | 0.0001 | 4.5 (2.2-9.4) |
T-stage | ||||||||
T1-T2a | Reference | Reference | Reference | Reference | ||||
T2b-T2c | 0.0065 | 2.0 (1.2-3.3) | 0.48 | 1.2 (0.70-2.2) | 0.82 | 1.1 (0.59-1.9) | 1.0 | 1.00 (0.55-1.8) |
T3-4 | <0.0001 | 3.3 (1.9-5.6) | 0.67 | 1.2 (0.60-2.2) | 0.83 | 1.1 (0.55-2.1) | 0.91 | 0.96 (0.49-1.9) |
Gleason Score | ||||||||
2-6 | Reference | Reference | Reference | Reference | ||||
7 | 0.0004 | 2.6 (1.5-4.3) | 0.17 | 1.6 (0.82-3.1) | 0.45 | 1.3 (0.67-2.5) | 0.58 | 1.2 (0.61-2.4) |
8-10 | <0.0001 | 4.9 (2.8-8.9) | 0.02 | 2.8 (1.2-6.9) | 0.027 | 2.8 (1.1-6.7) | 0.07 | 2.3 (0.93-5.8) |
ADT Use | ||||||||
No | Reference | Reference | Reference | Reference | ||||
Yes | 0.0001 | 2.2 (1.5-3.3) | 0.82 | 0.94 (0.53-1.7) | 0.68 | 0.88 (0.49-1.6) | 0.80 | 0.93 (0.51-1.7) |
Pelvic RT | ||||||||
No | Reference | Reference | Reference | Reference | ||||
Yes | <0.0001 | 2.7 (2.0-3.8) | 0.32 | 0.68 (0.32-1.5) | 0.20 | 0.59 (0.27-1.3) | 0.30 | 0.65 (0.29-1.5) |
RT Dose | 0.10 | 1.2 (0.97-1.4) | 0.95 | 1.01 (0.78-1.3) | 0.71 | 1.05 (0.82-1.3) | 0.70 | 1.05 (0.81-1.4) |
Cancer Volume Metrics | ||||||||
Maximum Biopsy Core | <0.0001 | 1.02 (1.01-1.02) | 0.12 | 1.01 (1.00-1.02) | 0.27 | 1.00 (0.99-1.02) | 0.33 | 1.00 (1.0-1.02) |
Percent Positive Cores | <0.0001 | 1.02 (1.01-1.03) | 0.019 | 1.01 (1.00-1.02) | ||||
Percent Cancer Volume | <0.0001 | 1.02 (1.02-1.03) | 0.03 | 1.02 (0.98-1.04) |